Clinical efficacy of CyberKnife radiotherapy for locally advanced pancreatic carcinoma

Abstract

Objective To assess the efficacy and safety of CyberKnife radiotherapy in the treatment of locally advanced pancreatic carcinoma. Methods The data of 59 patients with locally advanced pancreatic carcinoma who were treated with CyberKnife radiotherapy from 2006 to 2014 were retrospectively analyzed. The tumor volume ranged from 13. 0 cm3 to 125. 1 cm3 with a median value of 27. 1 cm3. A dose of 35-50 Gy(median value = 45 Gy)in 3-8 fractions(median value = 5 fractions)was prescribed. The tumor progression was evaluated based on computed tomography. The overall survival(OS)and local progression-free survival(LPFS)rates were calculated using the Kaplan-Meier method. Results The 1-and 2-year sample sizes were 26 and 17, respectively. The 1-and 2-year OS rates were 54% and 35%, respectively, while the 1-and 2-year LPFS rates were 91% and 70%, respectively. The median OS and LPFS times were 12. 5 and 10.9 months, respectively. The overall incidence of grade 1-2 acute and late gastrointestinal toxicity was 61%. One patient with grade 3 late gastrointestinal toxicity had incomplete intestinal obstruction. Conclusions CyberKnife radiotherapy can achieve excellent treatment outcomes and mild complications in the treatment of locally advanced pancreatic carcinoma. Key words: Pancreatic neolasms/CyberKnife radiotherapy; Treament outcome; Undoward effect